Theranostics is emerging as one of the most promising new approaches to cancer therapy,
with recently approved indications and over 500 active clinical trials currently underway
in patients with solid tumors and hematologic malignancies. This extends from early
phase academic trials to industry-sponsored, multicenter, multinational trials with
β and α particle emitting radioisotopes linked to targeting moieties.[1] The development of combined imaging and treatment approaches dates back to the development
of 131I therapy by Saul Hertz, and this treatment has been adopted globally for treatment
of hyperthyroidism and thyroid cancer.[1]
[2] More recent developments in theranostic treatment have been for selective delivery
of radiolabeled microspheres for liver cancer, 131I-MIBG for neuroblastoma, paraganglioma, and pheochromocytoma tumors, 177Lu-DOTATAE for neuroendocrine tumors, and 177Lu-PSMA for metastatic prostate cancer.[1]
[2]
[3]
[4]
[5]
[6] While the development and approval of theranostics has advanced dramatically over
the past 10 years, the availability of these treatments has been limited to mainly
high-income countries and has been the subject of a recent Lancet Oncology Commission
which outlined the challenges and opportunities for theranostics at a global level.[2]
In this special edition on theranostics, the key issues that are impacting on access
and availability of theranostics worldwide are reviewed, as well as the required expertise
and resources to implement and maintain successful theranostic programs. Brink et
al provide a perspective on the challenges and approaches to theranostics implementation
at a global level, and highlight the disparity in access and availability in many
countries.[6] They also provide information on the important role of the International Atomic
Energy Agency (IAEA) in addressing the key areas impacting on theranostics availability,
including workforce, guidelines, regulatory approaches, and radiopharmaceutical access.
The challenges in providing theranostics services is particularly relevant in low-
and middle-income countries (LMICs), and Lawal et al provide an important perspective
on how LMICs can implement theranostic programs, thus ensuring broader availability
for patients.[7] The lack of a suitably trained workforce is an issue in high-income countries and
LMICs, and guidelines for training nuclear medicine staff, as well as requirements
for theranostics centers, have been addressed in recent high-level reviews.[8]
[9]
[10]
The development of radiopharmaceuticals suitable for both imaging and therapy, and
access to these novel radiopharmaceuticals, is a crucial part of the ability to implement
a theranostics service.[2]
[11]
[12] While therapeutic β-particle emitting radioisotopes play a key role in most currently
approved theranostics, α-particle emitting radioisotopes are also emerging as highly
successful in treating advanced cancers.[1]
[2]
[11] In this edition, Bolin and Groves provide a comprehensive overview of α-particle
therapies approved and in development, and the practical aspects of handling both
α-particle radiopharmaceuticals and patients after treatment.[13] Radiation safety is an essential component of the practice of theranostics, and
guidelines for the safe and effective treatment of patients and management of staff
and the public remain a key focus for this treatment approach.[2]
[6]
[12] Procedure guidelines are also required to ensure patient selection, and treatment
for approved indications are performed to an appropriate standard.[2]
[6]
[14]
[15]
Dosimetry is also a key requirement for effective delivery of radiopharmaceuticals
for therapy.[2]
[6] Bailey et al provide a detailed overview of dosimetric approaches to radioembolization
therapy including practical implementation and patient workflow.[16] The approach to dosimetry in pediatric patients is addressed in two additional papers
in this edition. London et al provide a comprehensive overview of dosimetry approaches
to the delivery of theranostic treatment in pediatric patients with neuroblastoma,
with cases to demonstrate the implementation of this approach.[17] Trpezanovski et al outlines the implementation of dosimetry to guide treatment of
a young patient with a bronchial tumor, to achieve improved outcomes for the patient.[18] The use of personalized dosimetry for patient selection and treatment will be an
increasingly important component of theranostics practice in the future.[2]
The establishment of the safety and efficacy of theranostic treatments is essential
to obtain both regulatory and funding approvals, and both academic- and industry-sponsored
clinical trials are a key component of the requirement to generate the evidence required
for such approvals.[3]
[4]
[5] Pathmaraj and Lee provide an overview of the approaches to conducting clinical trials
in theranostics, including clinical trial networks and the need for multidisciplinary
care teams.[19] A highly successful example of an academic clinical trial network is the Australasian
Radiopharmaceutical Trials Network (ARTnet), and Francis et al provide a detailed
perspective on the establishment of ARTnet and the successful multicenter theranostics
trials conducted, which have led to regulatory approvals.[20] This type of academic, multicenter clinical trial network is being established in
many countries and regions to facilitate evidence of theranostics safety and efficacy
in different populations and is complementary to the large multicenter industry-sponsored
studies which are integral to the development of many new theranostic treatments.
The implementation of theranostics at a country level is often challenging, and different
parts of a country may find difficulties in staffing and logistics for access of radiopharmaceuticals
and delivery of treatments. In this edition, Steyn et al outline the development of
a national theranostics program for peptide-receptor radionuclide therapy, which has
been highly successful and may be a template for similar programs in many other countries.[21] Morigi and McGavin provide an overview of a successful implementation of a positron
emission tomography imaging service in a remote country location, highlighting the
strategies required to achieve this outcome.[22] The clinical implementation of theranostics is one of the greatest challenges for
nuclear medicine at a global level, but brings the potential for transformative impact
for our field. The opportunities for theranostics and approaches for implementation
outlined in this edition will contribute to highly impactful outcomes for our patients
and families.
